GlassScriptPhysician profile
Shabbir Reza
NPI 1811169543
$3,290.56
in general payments reported to CMS, 2019-2025
26 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.85 · 2022: $313 · 2023: $1,080 · 2024: $1,020 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,953.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $565.98 | 2022-2025 | Cardiomems, Jot Dx |
| Amgen INC. | $304.29 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $300.54 | 2023-2025 | |
| Boston Scientific Corporation | $257.15 | 2022-2023 | Watchman Access System |
| Edwards Lifesciences Corporation | $245.81 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Pfizer INC. | $227.07 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.30 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $176.05 | 2023-2025 | Jardiance, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $167.87 | 2024-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $145.31 | 2022-2025 | Farxiga, Wainua |
| Impulse Dynamics (USA) INC. | $111.05 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $96.95 | 2024 | Arcalyst |
| Novo Nordisk INC | $77.63 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Medtronic, INC. | $77.62 | 2024-2025 | Symplicity G3, Linq II |
| Janssen Pharmaceuticals, INC | $70.39 | 2020-2023 | Xarelto |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $62.40 | 2024-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $53.85 | 2023-2025 | Onpattro |
| Kiniksa Pharmaceuticals, LTD. | $41.05 | 2023 | Arcalyst |
| Baxter Healthcare | $23.09 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Lexicon Pharmaceuticals, INC. | $22.80 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $19.61 | 2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $19.25 | 2023 | Verquvo |
| Sanofi-Aventis U.S. LLC | $18.32 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $15.43 | 2024 | Livalo |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shabbir Reza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.